Dravet syndrome (DS), a rare form of epilepsy, occurs in approximately 1 in 20,000 live births and is associated with a significant humanistic and economic burden on caregivers, families, and patients. While many medications are used in treating the seizures associated with DS, there are currently no FDA-approved treatments, and nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime. Several investigational therapies are in late-stage development with the potential to provide new treatment options to address the serious medical needs for patients with DS.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with Dravet syndrome.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

1. Summarize the epidemiology of DS
2. Identify the burden of illness of DS, including sudden unexpected death in epilepsy (SUDEP)
3. Cite mechanisms of action and key clinical trial data for therapies for DS in late-stage development
4. Review emerging preclinical models for SUDEP prevention

FACULTY

	Linda C. Laux, MD (Program Chair) Medical Director Comprehensive Epilepsy Center Assistant Professor of Pediatrics Feinberg School of Medicine Northwestern University Chicago, Illinois
	Kelly G. Knupp, MD, MSCS, FAES Associate Professor of Pediatrics and Neurology Neurology and Neurodiagnostics Children’s Hospital Colorado, University of Colorado Denver Denver, Colorado
	Lieven G. Lagae, MD, PhD Professor of Paediatric Neurology Director of Paediatric Neurology University Hospitals Leuven – Paediatric Neurology Leuven, Flanders, Belgium
	Joseph E. Sullivan, MD Associate Professor of Neurology & Pediatrics University of California, San Francisco (UCSF) Director, UCSF Pediatric Epilepsy Center of Excellence San Francisco, California
	Nicole Villas, MEd Board President Dravet Syndrome Foundation Cherry Hill, New Jersey

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Zogenix, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., and Zogenix, Inc., do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.